Podcasts about Sickle cell disease

In this Rising Star episode from the NASCC meeting in Stowe, Vermont, Dr. Z and Dr. C spotlight Dr. Alyssa Schlenz, a psychologist transforming sickle cell care through early developmental screening and neuropsychological support. Dr. Schlenz shares her journey into the field, the critical role of prevention and early intervention, and the unique challenges faced by patients with neurodevelopmental disorders. She explains how routine, relationship-based screenings can identify issues early, reduce stigma, and improve long-term outcomes. This inspiring conversation highlights the power of psychology in comprehensive sickle cell care and the promising future being shaped by dedicated new leaders. SHOW DESCRIPTION Cheat Codes is intended for patients, caregivers, providers, and the greater community of people who are impacted by Sickle Cell Disease.  Each episode, Cheat Codes strives to provide listeners with critical education, the latest scientific updates, and voices from the Sickle Cell community.   Join an inclusive community and build connections with other hemolytic anemia allies by following @AllyVoicesRising on Instagram.

Eberechi Nwogu-Onyemkpa is an assistant professor in the Division of Palliative Medicine at Washington University in St. Louis. Stephen Morrissey, the interviewer, is the Executive Managing Editor of the Journal. E. Nwogu-Onyemkpa and Others. Involving Palliative Care to Improve Outcomes in Sickle Cell Disease. N Engl J Med 2025;393:1553-1556. E. Costa and Others. Thirty Years of Hydroxyurea for Sickle Cell Anemia — Scientific Progress, Global Health Gaps. N Engl J Med 2025;393:1556-1559.

Avec Annie Viau, pharmacienne, et Maria Tamer, infirmière praticienne spécialisée en soins pédiatriques, nous allons:définir l'anémie falciforme (drépanocytose) et comprendre sa physiopathologie;   distinguer les principales complications possibles et leur prise en charge respective; discuter des traitements de base de l'anémie falciforme. RéférencesAmerican Society of Hematology. (2025). Sickle cell disease timeline.Société canadienne de pédiatrie (2022). La prévention et la prise en charge des complications aiguës de l'anémie falciforme.Société canadienne de pédiatrie (2024). La prévention et le traitement des infections chez les enfants présentant une asplénie ou une hyposplénie. Protocole HSJ. (2025) Anémie falciforme.CHU Sainte-Justine. (2025) Anémie falciforme. George, A., et al. (2024). Splenic complications in pediatric sickle cell disease: A retrospective cohort review. Pediatric Blood & Cancer, 71(10).Kavanagh, P. L., et al. (2022). Sickle cell disease: A review. JAMA, 328(1).Kazadi, C., Ducruet, T., Forté, S., Robitaille, N., & Pastore, Y. (2024). Positive impacts of universal newborn screening on the outcome of children with sickle cell disease in the province of Quebec: A retrospective cohort study. EJHaem, 5(3).Société canadienne du sang. (202). Anémie falciforme et don de sang.CHU de Québec. (2025). Programme québécois de dépistage néonatal sanguin.Pastore, Y., & Robitaille, N. (2024). Bilan de 10 ans de dépistage des anomalies de l'hémoglobine au Québec [Présentation]. Ministère de la Santé et des Services sociaux.Association de l'anémie falciforme du Canada.Grégoire-Pelchat, P., Alos, N., Ribault, V., Pastore, Y., Robitaille, N., & Mailhot, G. (2018). Vitamin D Intake and Status of Children With Sickle Cell Disease in Montreal, Canada. J Pediatr Hematol Oncol., 40(8).Les invité(e)s et l'animatrice ne déclarent aucun conflit d'intérêt. Idée originale, réalisation et animation: Émilie Roy-St-PierreCaptation et montage: Antoine Palardy (depuis octobre 2025) et Philippe Lacroix (janvier 2024 à octobre 2025), spécialistes en audiovisuelConseillère en communication: Pascale Chatagnier (depuis mai 2025) ; Katrine Louis-Seize (janvier 2024 à mai 2025)Logo: Équipe des communications et du graphisme du CHU Sainte-JustineMusique: Samuel RossCollègues, ami(e)s et famille, merci pour votre précieux soutien. © mgparkilo 2025 Merci pour l'écoute! Allez mettre une réaction sur vos épisodes préférés, partagez la bonne nouvelle sur Facebook/Instagram et abonnez-vous pour ne rien manquer

In this live episode from the NASCC meeting in Stowe, Vermont, Dr. Z and Dr. C are joined by a powerhouse panel: Dr. Payel Desai, Dr. Seethal Jacob, Dr. Pat McGann, and Dr. Andy Ellner to unpack what truly defines great sickle cell care. The group explores the importance of comprehensive, continuous, and patient-centered models, from inpatient to outpatient settings, pediatrics to adulthood. They discuss integrating technology, clinical trials, and multidisciplinary teams to improve quality of life and prevent long-term complications. It's an insightful look at how collaboration, innovation, and trust are shaping the future of sickle cell treatment.   SHOW DESCRIPTION Cheat Codes is intended for patients, caregivers, providers, and the greater community of people who are impacted by Sickle Cell Disease. With each episode, Cheat Codes strives to provide listeners with critical education, the latest scientific updates, and voices from the Sickle Cell community.     Join an inclusive community and build connections with other hemolytic anemia allies by following @AllyVoicesRising on Instagram.   TRANSPARENCY STATEMENT  Cheat Codes: A Sickle Cell Podcast is made possible by Agios Pharmaceuticals Inc. Visit Agios.com to learn more. The following Agios-supported programs are intended for informational and educational purposes only and are not intended as medical advice. Please speak with your healthcare professional before making any treatment decisions. Host and guests featured in this episode have been compensated for their time.  

Sickle cell disease was once considered an incurable disease, until recently. A wide variety of gene therapies have now become available, allowing patients with sickle cell disease to now have futures once thought unimaginable. In this podcast episode, we talk through these treatments and get expert advice on what these treatments mean for our future. 

Guest: Alexis Leonard With two FDA-approved gene therapies, including the first CRISPR-based treatment, curative strategies for sickle cell disease are continuing to expand the treatment landscape. However, challenges remain in optimizing safety and accessibility, particularly for patients unable to tolerate current myeloablative conditioning. Learn about advancements in ex vivo editing, such as improved stem cell targeting and multiplex editing, and the possibility of in vivo approaches that may help transform sickle cell disease management with Dr. Alexis Leonard, who works in the Department of Hematology at St. Jude's Hospital in Memphis, Tennessee.

Guest: David Jacobsohn Gene therapy is redefining the treatment landscape for sickle cell disease, with approaches like gene addition, gene editing, and fetal hemoglobin induction showing promise in reducing or even eliminating symptoms. However, while these therapies offer some advantages over allogeneic stem cell transplant, they also come with significant challenges. In a conversation with Ryan Quigley, Dr. David Jacobsohn discusses considerations for these therapeutic approaches and their potential impacts on care plans for sickle cell disease patients. Dr. Jacobsohn is the Division Chief of the Blood and Marrow Transplantation Program at Children's National Hospital and Full Professor of Pediatrics at the George Washington University in Washington, DC.

Guest: Alexis Leonard Sickle cell disease management traditionally involves two primary treatment approaches: disease-modifying therapies and curative strategies. While disease-modifying therapies can help reduce complications associated with the disease, they do not correct or fix them, which is why curative strategies are appealing to some patients and physicians. Join Dr. Alexis Leonard as she discusses the current management landscape for sickle cell disease, including disease-modifying treatments, curative strategies, and potential gene therapies. Dr. Leonard works in the Department of Hematology at St. Jude's Hospital in Memphis, Tennessee.

As Sickle Cell Awareness Month comes to a close, we revisit our conversation with Tahirah Austin-Muhammad, who was diagnosed with sickle cell disease when she was six years old. Throughout her life, she has dealt with pain and organ failures. In 2024, she was on the waiting list for a kidney transplant, living on 7% kidney function. Despite that, she has raised a daughter and helped found ⁠Crescent Foundation⁠ to provide education and resources to others living with sickle cell disease. Racquel Williams talks with Tahirah along with her physician, Dr. Safiyya Shabazz.  Learn more about how to find and support Black physicians in the Philadelphia area from ⁠The Medical Society of Eastern Pennsylvania⁠. Then, on Shara in the City, we're treating ourselves to a little something sweet at Reading Terminal Market. Shara Dae Howard visits ⁠Sweet Nina's⁠ to learn about the local business and taste their wide array of banana pudding flavors. The sickle cell interview was originally released on May 18, 2024. Shara in the City at Sweet Nina's was originally released on August 2, 2025. To learn more about listener data and our privacy practices visit: https://www.audacyinc.com/privacy-policy Learn more about your ad choices. Visit https://podcastchoices.com/adchoices

In this episode of Cheat Codes, Dr. Z and Dr. C sit down with Dr. Julie Kanter, Dr. Sophie Lanzkron, and Dr. Marsha Treadwell to spotlight the National Alliance of Sickle Cell Centers (NASCC). They explore how NASCC came to life, its mission to unite multidisciplinary teams, and its role in setting consensus guidelines for sickle cell care. From building a national registry to fostering collaboration between clinics, community organizations, and patients, the conversation captures a pivotal movement toward consistent, high-quality care nationwide. Listeners will hear how NASCC is shaping the present—and future—of sickle cell treatment.   For more information on the National Alliance of Sickle Cell Centers (NASCC), please visit: https://sicklecellcenters.org/   SHOW DESCRIPTION Cheat Codes is intended for patients, caregivers, providers, and the greater community of people who are impacted by Sickle Cell Disease.  Each episode, Cheat Codes strives to provide listeners with critical education, the latest scientific updates, and voices from the Sickle Cell community.     Join an inclusive community and build connections with other hemolytic anemia allies by following @AllyVoicesRising on Instagram.   TRANSPARENCY STATEMENT  Cheat Codes: A Sickle Cell Podcast is made possible by Agios Pharmaceuticals Inc. Visit Agios.com to learn more. The following Agios-supported programs are intended for informational and educational purposes only and are not intended as medical advice. Please speak with your healthcare professional before making any treatment decisions. Host and guests featured in this episode have been compensated for their time.  

Discover the powerful history of Trinidad as Diane Hinds, entertainment publicist and author of Conquerabia: The Struggle for Identity, unpacks the island's colonial past, the fight for identity, and the enduring impact of slavery and resistance. Learn how historical fiction can reshape narratives and why reclaiming lost voices is more important than ever. This insightful conversation is a must-watch for history lovers, writers, and cultural enthusiasts.==========================================

Combating the Opioid crisis in the capital city. Fentanyl Harm Prevention Kits and Emergency Overdose Boxes are now in the hands of first responders.Then, a new online tool is launched to address Mississippi's childcare shortages. Plus, Sickle Cell disease causes severe pain and even death. Efforts are underway to raise awareness about the disease and find a cure. Hosted on Acast. See acast.com/privacy for more information.

Event Objectives:Identify at least two systemic factors contributing to poor health outcomes in youth with sickle cell disease.Explain the impact of provider bias on health outcomes in pediatric sickle cell disease.Describe two bias-mitigating strategies that can be used by health care providers.Claim CME Credit Here!

Host: Ashley Baker, MSN, PMHNP Guest: Alyssa Schlenz Guest: Shannon Phillps Families of children with sickle cell disease have noted both an abundance of support and significant obstacles when accessing care, ranging from knowledgeable providers and flexible scheduling to transportation concerns and insurance holdups. Joining Ashley Baker to discuss their recent research on these key facilitators and barriers are Drs. Alyssa Schlenz and Shannon Phillips. Dr. Schlenz is an Associate Professor of Pediatrics at the University of Colorado School of Medicine, and Dr. Phillips is an Associate Professor in the College of Nursing at the Medical University of South Carolina.

In this episode of Cheat Codes, Dr. Z and Dr. C are joined by renowned advocates TaLana Hughes and Cassandra Trimnell to explore what “the sickle cell community” truly means. They discuss how patients, caregivers, providers, and allies form interconnected, and often overlapping, communities that bring hope, support, and change. From building trust to celebrating wins, the conversation highlights the power of connection, the importance of access to information, and how to find your “tribe” in the sickle cell space. Whether local or global, online or in person, community remains the heartbeat of progress in sickle cell disease.   SHOW DESCRIPTION Cheat Codes is intended for patients, caregivers, providers, and the greater community of people who are impacted by Sickle Cell Disease.  Each episode, Cheat Codes strives to provide listeners with critical education, the latest scientific updates, and voices from the Sickle Cell community.     Join an inclusive community and build connections with other hemolytic anemia allies by following @AllyVoicesRising on Instagram.   TRANSPARENCY STATEMENT  Cheat Codes: A Sickle Cell Podcast is made possible by Agios Pharmaceuticals Inc. Visit Agios.com to learn more. The following Agios-supported programs are intended for informational and educational purposes only and are not intended as medical advice. Please speak with your healthcare professional before making any treatment decisions. Host and guests featured in this episode have been compensated for their time.  

Courtney is living her best life, enjoying time with friends in New York City and working hard as she establishes her career. She also has sickle cell disease. And she deals with the physical and emotional effects of it day in and day out.Sickle cell disease is an inherited disorder that affects about 100,000 people in the United States, predominantly African Americans. The disease affects red blood cells. Normally, they're round and plump. Sickle cell disease warps them into crescent shapes. That makes them less flexible and less able to carry oxygen to internal organs. A person with sickle cell disease faces a lifetime of potential health complications like heart disease, kidney disease, stroke, and frequent bouts of intense pain.In this conversation, Courtney talks about the care and education about sickle cell disease she received as a patient at St. Jude Children's Research Hospital. She says it's important to find community, to have a strong base of support, and to know how to advocate for yourself.Courtney was one of the very first babies at St. Jude to be part of a study called BABYHUG. It helped pave the way for a medication called hydroxyurea to be approved for young children with sickle cell disease. She has high hopes for more innovations in treatment in the future.St. Jude is the primary treatment center for children with sickle cell disease in the Memphis area, and it is also one of the largest sickle cell disease programs in the country. In 1983, a St. Jude patient was the first person to be cured of sickle cell disease through a bone marrow transplant. Today, in addition to participating in and leading several clinical trials studying the use of hydroxyurea in children, St. Jude is also studying gene therapy as a potential cure for sickle cell disease as well as techniques to make stem cell transplantation less risky and more broadly accessible.You can find more information about research into sickle cell disease and the patients and families who find care at St. Jude herehttps://www.stjude.org/get-involved/other-ways/sickle-cell-awareness-month.html#impact

a focus on its acute presentations and the care we can deliver to improve outcomes for our patients. Sickle cell disease (SCD) is a lifelong inherited blood disorder that affects over 15,000 people in the UK, and millions worldwide. It's caused by the production of abnormal haemoglobin molecules, which distort red blood cells into a crescent, or “sickle,” shape. These rigid cells can block small blood vessels, leading to painful vaso-occlusive crises and organ damage. While the condition has long been most prevalent in parts of Africa, the Middle East, the Mediterranean and India, today it's a global health issue, and one we encounter regularly in UK emergency care. Tragically, failings in care have too often led to avoidable harm. The 2021 parliamentary report “No One's Listening” laid bare some of these cases, highlighting missed opportunities, poor awareness, and systemic issues that cost lives, such as the death of Evan Nathan Smith. So why are we revisiting this now? In 2024, RCEM published new Best Practice Guidelines on managing sickle cell disease in the ED. These provide clear, evidence-based standards for recognition, triage, analgesia, infection control, and safe discharge. In this episode, we take you through the key elements; Pathophysiology – how a genetic mutation drives sickling, vaso-occlusion and inflammation. Clinical presentations – from painful crises and acute chest syndrome, to stroke, anaemia, infection, priapism and pregnancy-related complications. Recognition and triage – why timely pain control within 30 minutes is a must, and how to spot red flags. Investigations and treatment – including the role of reticulocytes, the importance of knowing a patient's baseline haemoglobin, and principles of analgesia, transfusion, oxygen, and supportive care. Discharge and ongoing care – ensuring safe, joined-up planning, and involving haematology and specialist pathways wherever possible. The take-home message? Every sickle cell crisis is a medical emergency. We need to listen to patients, escalate early, involve haematology, and deliver care that meets the standards they deserve. Once again we'd love to hear any thoughts or feedback either on the website or via X @TheResusRoom! Simon, Rob & James

A study finds that fewer than half of children with sickle cell disease covered by Michigan Medicaid received dental services. Read the full story on Health Lab.Episode TranscriptFor more on this story and for others like it, visit the Health Lab website where you can subscribe to our Health Lab newsletters to receive the latest in health research and information to your inbox each week. Health Lab is a part of the Michigan Medicine Podcast Network, and is produced by the Michigan Medicine Department of Communication. You can listen to Health Lab wherever you get your podcasts.All Health Lab content including health news, best practices and research insights are for informational purposes only and are not a substitute for professional medical guidance. Always seek the advice of a health care provider for questions about your health and treatment options. Hosted on Acast. See acast.com/privacy for more information.

About this episode:  Sickle cell disease affects an estimated 100,000 people in the United States. Recent advancements in gene therapies and medicines like hydroxyurea are diminishing extreme pain, reducing strokes, and extending survival times for those afflicted by the disease. In this episode: leading sickle cell disease expert Dr. Mark Gladwin explains how revolutionary new treatments work and discusses the challenges to access to life-saving care. Guest: Dr. Mark Gladwin is a physician-scientist and the Dean of the University of Maryland School of Medicine and Vice President for Medical Affairs at the University of Maryland, Baltimore. His research focuses include sickle cell disease and hypertension. Host: Dr. Josh Sharfstein is vice dean for public health practice and community engagement at the Johns Hopkins Bloomberg School of Public Health, a faculty member in health policy, a pediatrician, and former secretary of Maryland's Health Department. Show links and related content: New sickle cell gene therapies are a breakthrough, but solving how to pay their high prices is a struggle—CNBC Gene Therapy: What You Need to Know—Sickle Cell Disease Association of American No More Pain: Breakthrough Sickle Cell Treatment from Johns Hopkins Offers Curative Potential—Johns Hopkins School of Medicine Transcript information: Looking for episode transcripts? Open our podcast on the Apple Podcasts app (desktop or mobile) or the Spotify mobile app to access an auto-generated transcript of any episode. Closed captioning is also available for every episode on our YouTube channel. Contact us: Have a question about something you heard? Looking for a transcript? Want to suggest a topic or guest? Contact us via email or visit our website. Follow us: @‌PublicHealthPod on Bluesky @‌JohnsHopkinsSPH on Instagram @‌JohnsHopkinsSPH on Facebook @‌PublicHealthOnCall on YouTube Here's our RSS feed Note: These podcasts are a conversation between the participants, and do not represent the position of Johns Hopkins University.

In this episode, host Jonathan Sackier is joined by Emanuele Angelucci, Director of Hematology and Cellular Therapies and Director of the Stem Cell Transplant and Cellular Therapies Program at the Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Ospedale Policlinico San Martino Hospital in Genoa, Italy.   Timestamps   00:00 – Introduction 02:14 – The future of stem cell transplantation 03:15 – What continues to drive Emanuele in his work 05:40 – Donation of haematopoietic stem cells 10:00 – Gene therapy for haemoglobinopathies 11:40 – Will stem cell transplantation remain central in treating thalassaemia and sickle cell disease? 14:14 – Emanuele's work on iron overload and toxicity 16:53 – Current landscape for haemoglobinopathies 22:11 – Key recommendations in the most recent clinical guidelines for haemoglobinopathies  25:00 – Promising developments on the horizon for patients with haemoglobinopathies  28:00 – Emanuele's key takeaways 

On tonight's program: The build out of Alligator Alcatraz is on hold. At least for the time being; It seems Texas and California aren't the only states thinking about redrawing congressional district maps; Pill mills used to be a big problem in Florida. Now, it appears that problem may be emerging again; More state money is on its way to battling Sickle Cell Disease in Florida; Despite protests, it looks like some colorful street art that flies in the face of official state policy in Florida may be disappearing; A federal plan to lower the sugar requirement for orange juice may help Florida's struggling citrus industry; A green sea turtle, rescued earlier this year and nursed back to health, is helping researchers find out more about her species; And we'll be among the first to hear the sound of a stingray eating lunch, and learn why these unique sea creatures are perhaps more important than we realized.

Gene therapy for sickle cell disease—patient perspective by TRANSFUSION's Monthly Podcast

Guest: Abiodun Ologunowa Pediatric sickle cell disease treatment, particularly the use of hydroxyurea, NSAIDs, and opioids, has evolved in response to clinical guidelines and regulatory shifts, but gaps still remain in how children receive essential medications. Joining Dr. Charles Turck to discuss these national prescribing trends, disparities in care, and the implications of evolving treatment guidelines for this population is Dr. Abiodun Ologunowa. Dr. Ologunowa is a doctoral candidate and research assistant in the Department of Pharmacy Practice and Clinical Research at the University of Rhode Island College of Pharmacy.

Guest: Abiodun Ologunowa Pediatric sickle cell disease treatment, particularly the use of hydroxyurea, NSAIDs, and opioids, has evolved in response to clinical guidelines and regulatory shifts, but gaps still remain in how children receive essential medications. Joining Dr. Charles Turck to discuss these national prescribing trends, disparities in care, and the implications of evolving treatment guidelines for this population is Dr. Abiodun Ologunowa. Dr. Ologunowa is a doctoral candidate and research assistant in the Department of Pharmacy Practice and Clinical Research at the University of Rhode Island College of Pharmacy.

Guest: Abiodun Ologunowa Pediatric sickle cell disease treatment, particularly the use of hydroxyurea, NSAIDs, and opioids, has evolved in response to clinical guidelines and regulatory shifts, but gaps still remain in how children receive essential medications. Joining Dr. Charles Turck to discuss these national prescribing trends, disparities in care, and the implications of evolving treatment guidelines for this population is Dr. Abiodun Ologunowa. Dr. Ologunowa is a doctoral candidate and research assistant in the Department of Pharmacy Practice and Clinical Research at the University of Rhode Island College of Pharmacy.

In this episode, host Jonathan Sackier is joined by Steven Okoli, Honorary Senior Clinical Lecturer at Imperial College London. From leading the UK's first adult stem cell transplant trial for sickle cell disease to driving innovation in AI-guided transfusion strategies, Okoli shares how clinical research, patient advocacy, and equity-driven care are reshaping the landscape of haemoglobinopathies in the UK and beyond.  Timestamps  00:00: Introduction  01:58: Quickfire round  09:09: Pioneering adult stem cell transplant in sickle cell  11:41: Combining AI and genetics for blood transfusion  13:58: Systemic disparities in sickle cell  20:58: Education and advocacy  23:30: Non-cancerous blood disorders  25:18: What's next in sickle cell?  27:27: Okoli's three wishes for healthcare  

Guest: Yogindra Persuad Despite the promise of curative therapies for sickle cell disease, access and cost barriers highlight the ongoing need for disease-modifying treatments like hydroxyurea. Tune in to hear Dr. Yogindra Persuad, a physician in the Department of Hematology at St. Jude Children's Research Hospital in Memphis, Tennessee, discuss a multimodal approach to care, emphasizing research on oral agents and broader symptom management beyond pain.

Guest: Yogindra Persuad Despite the promise of curative therapies for sickle cell disease, access and cost barriers highlight the ongoing need for disease-modifying treatments like hydroxyurea. Tune in to hear Dr. Yogindra Persuad, a physician in the Department of Hematology at St. Jude Children's Research Hospital in Memphis, Tennessee, discuss a multimodal approach to care, emphasizing research on oral agents and broader symptom management beyond pain.

In this week's episode we'll learn more about the use of ruxolitinib plus dexamethasone to treat newly diagnosed patients with adult hemophagocytic lymphohistiocytosis; lysine-specific demethylase-1 inhibitors as a potential new class of therapies for sickle cell disease and other beta-globinopathies; and insights into clinical characteristics of patients with von Willebrand factor levels that are lower than normal but higher than those typically used to diagnose von Willebrand disease.Featured Articles:Ruxolitinib combined with dexamethasone for adult patients with newly diagnosed hemophagocytic lymphohistiocytosis in ChinaNovel, potent, and orally bioavailable LSD1 inhibitors induce fetal hemoglobin synthesis in a sickle cell disease mouse modelClinical phenotype and pathophysiological mechanisms underlying qualitative low VWF

Guest: Parul Rai Hydroxyurea and chronic transfusions remain cornerstone therapies in managing sickle cell disease, with proven benefits in reducing stroke risk and improving anemia. However, considerations remain, including their impact on cardiac health. Learn about these long-standing therapies and best practices for using them to manage sickle cell disease with Dr. Parul Rai. Dr. Rai is a physician in the Department of Hematology at St. Jude's Hospital in Memphis, Tennessee.

Guest: Parul Rai Cardiopulmonary complications are a leading cause of early mortality in adults with sickle cell disease, with evidence showing that cardiac injury may begin as early as childhood. However, despite the severity of these issues, there are currently no uniform guidelines for asymptomatic cardiac screening in this population. Join Dr. Parul Rai, a physician in the Department of Hematology at St. Jude's Hospital in Memphis, Tennessee, to learn about current research, early detection strategies, and the need for more sensitive diagnostic markers to prevent severe cardiac outcomes in patients with sickle cell disease.

Guest: Nidhi Bhatt Effective transition from pediatric to adult care should begin as early as age twelve for patients with sickle cell disease, incorporating factors like education, self-advocacy skills, and support from transition care coordinators. Tune in to hear Dr. Nidhi Bhatt, who works in the Department of Hematology at St. Jude Children's Hospital in Memphis, Tennessee, discuss how involving patients and families early on helps identify barriers and improve long-term outcomes.

Guest: Parul Rai Hydroxyurea and chronic transfusions remain cornerstone therapies in managing sickle cell disease, with proven benefits in reducing stroke risk and improving anemia. However, considerations remain, including their impact on cardiac health. Learn about these long-standing therapies and best practices for using them to manage sickle cell disease with Dr. Parul Rai. Dr. Rai is a physician in the Department of Hematology at St. Jude's Hospital in Memphis, Tennessee.

Guest: Nidhi Bhatt Effective transition from pediatric to adult care should begin as early as age twelve for patients with sickle cell disease, incorporating factors like education, self-advocacy skills, and support from transition care coordinators. Tune in to hear Dr. Nidhi Bhatt, who works in the Department of Hematology at St. Jude Children's Hospital in Memphis, Tennessee, discuss how involving patients and families early on helps identify barriers and improve long-term outcomes.

Guest: Parul Rai Cardiopulmonary complications are a leading cause of early mortality in adults with sickle cell disease, with evidence showing that cardiac injury may begin as early as childhood. However, despite the severity of these issues, there are currently no uniform guidelines for asymptomatic cardiac screening in this population. Join Dr. Parul Rai, a physician in the Department of Hematology at St. Jude's Hospital in Memphis, Tennessee, to learn about current research, early detection strategies, and the need for more sensitive diagnostic markers to prevent severe cardiac outcomes in patients with sickle cell disease.

So far in 2025, the Trump administration has cut more than $1 billion in NIH grants. That includes a study on sickle cell disease, a blood disorder that affects roughly 100,000 people in the U.S. According to the CDC, 90% of them are Black. Ali Rogin speaks with Dr. Charity Oyedeji, a Duke University hematologist whose research grant was terminated, to learn more. PBS News is supported by - https://www.pbs.org/newshour/about/funders

So far in 2025, the Trump administration has cut more than $1 billion in NIH grants. That includes a study on sickle cell disease, a blood disorder that affects roughly 100,000 people in the U.S. According to the CDC, 90% of them are Black. Ali Rogin speaks with Dr. Charity Oyedeji, a Duke University hematologist whose research grant was terminated, to learn more. PBS News is supported by - https://www.pbs.org/newshour/about/funders

Not everyone's brain ages at the same rate. Andria L. Ford, professor of neurology, adult stroke & cerebrovascular disease at Washington University of St. Louis Medicine, looks into one reason why. Dr. Andria L. Ford is a neurologist at WashU Medicine specializing in stroke, cerebrovascular diseases, and the neurological complications of sickle cell disease. Her […]

This week Dr Amy Webster joins us again for part two of our Sickle Cell Disease series. This week we discuss treatment of outpatients with Sickle cell, and cover what to do when patients are admitted with acute crisis. If you have time, filling out our feedback survey will help us improve the podcast!Check out our Link-tree below:https://linktr.ee/memcast?fbclid=PAZXh0bgNhZW0CMTEAAac5brlP9e4auOdiois6KsQcdonp35db0RuUXgHue3KxvmTMG-ZM70o63vbLlQ_aem_aSMbpAFUEbimdv46iRnjTA

Send us a Text Message (please include your email so we can respond!)Episode 66! Today we talk about Acute Chest Syndrome in Sickle Cell Disease with one of our favorite hematologists, Benjamin Tillman! We base our discussion around the TASC trial or "Comparison of Prophylactic and Therapeutic Doses of Anticoagulation for Acute Chest Syndrome in Sickle Cell Disease" published by Dessap et al in AJRCCM April of 2025.Pubmed: https://pubmed.ncbi.nlm.nih.gov/40209087/AJRCCM: https://www.atsjournals.org/doi/10.1164/rccm.202409-1727OCIf you enjoy the show be sure to like and subscribe, leave that 5 star review! Be sure to follow us on the social @icucast for the associated figures, comments, and other content not available in the audio format! Email us at icuedandtoddcast@gmail.com with any questions or suggestions! Thank you Mike Gannon for the intro and exit music!

Sickle cell disease is a genetic abnormality that causes red blood cells to sickle instead of being round, and a host of problems result, including excruciatingly painful sickle cell crises. Rick Jones, an expert in blood disorders and cancer at … What's the best way to cure sickle cell disease? Elizabeth Tracey reports Read More »

Bone marrow transplants used to be limited to just those people with sickle cell disease who could receive bone marrow from a matched donor. Rick Jones, an expert in blood disorders and cancers at Johns Hopkins, and colleagues have just … A new technique cures most people with sickle cell disease, Elizabeth Tracey reports Read More »

Headlines have announced that sickle cell disease can be cured with gene therapy. Now there's a better way developed at Johns Hopkins and other centers around the world, using what are called ‘half-matched donors,' to give new bone marrow to … A new technique is better than gene therapy for curing sickle cell disease, Elizabeth Tracey reports Read More »

Gene therapy for sickle cell disease has a breathtaking price tag of 2-3 million dollars per person, and for some people who receive it, is doesn't actually cure the condition. That's according to Richard Brodsky, a sickle cell expert at … Gene therapy for sickle cell disease often isn't a cure, Elizabeth Tracey reports Read More »

Sickle cell disease was thought to be cured using gene therapy, but longer term follow up reveals that while the condition improves many are not cured. Now a new approach developed at Johns Hopkins and around the world uses ‘half-matched' … Sickle cell disease should be treated with a half-matched donor approach, Elizabeth Tracey reports Read More »

In the March 2025 episode of Critical Decisions in Emergency Medicine, Drs. Danya Khoujah and Wendy Chang discuss pediatric sickle cell disease and trauma-informed care. As always, you'll also hear about the hot topics covered in Critical Decisions' regular features, including a child with difficulty walking in Clinical Pediatrics, sternoclavicular joint septic arthritis in Orthopedics and Trauma, interscalene nerve block in The Critical Procedure, intranasal topical application of tranexamic acid for atraumatic anterior epistaxis in The LLSA Literature Review, and a toddler with arm pain in The Critical Image.

On this episode of Cheat Codes, guest host Janie Davis, Director of Patient Advocacy at Agios Pharmaceuticals, is joined by sickle cell advocates Teonna Woolford, Cassandra Trimnell, and Rae Blaylark discuss the challenges and rewards of sickle cell advocacy. They delve into personal journeys, the nuances of advocacy, and the importance of self-care. The conversation highlights the power of community, the significance of setting boundaries, and the need for therapeutic support. The advocates also reflect on the impact of their work and offer advice for the next generation of sickle cell advocates.   SHOW DESCRIPTION Cheat Codes is intended for patients, caregivers, providers, and the greater community of people who are impacted by Sickle Cell Disease.  Each episode, Cheat Codes strives to provide listeners with critical education, the latest scientific updates, and voices from the Sickle Cell community.     Join an inclusive community and build connections with other hemolytic anemia allies by following @AllyVoicesRising on Instagram.   TRANSPARENCY STATEMENT  Cheat Codes: A Sickle Cell Podcast is made possible by Agios Pharmaceuticals Inc. Visit Agios.com to learn more. The following Agios-supported programs are intended for informational and educational purposes only and are not intended as medical advice. Please speak with your healthcare professional before making any treatment decisions. Host and guests featured in this episode have been compensated for their time.  

In this week's episode, we'll learn more about how measurable residual disease might help guide decisions about post-transplant gilteritinib maintenance in FLT3-ITD acute myeloid leukemia, or AML; how stemness contributes to chemotherapy resistance in AML; and effects of babesiosis on red blood cells from individuals with sickle cell disease, sickle cell trait, and wild-type hemoglobin. Featured Articles:Measurable residual disease and post-transplantation gilteritinib maintenance for patients with FLT3-ITD-mutated AML GATA2 links stemness to chemotherapy resistance in acute myeloid leukemia Babesiosis and Sickle Red Blood Cells: Loss of Deformability, Heightened Osmotic fragility and Hyper-vesiculation 

On this episode, Dr. Z and Dr. C. Callahan interview Dr. Isaac Odame, a leading figure in the field of sickle cell disease. Dr. Odame shares his life story, beginning in Ghana, his medical training in the UK, and his global contributions to sickle cell research, including involvement with the Global Sickle Cell Disease Network. The discussion covers his work in various countries, the challenges, and successes in treating sickle cell disease, and his family's influence on his career.    SHOW DESCRIPTION Cheat Codes is intended for patients, caregivers, providers, and the greater community of people who are impacted by Sickle Cell Disease.  Each episode, Cheat Codes strives to provide listeners with critical education, the latest scientific updates, and voices from the Sickle Cell community.     TRANSPARENCY STATEMENT  Cheat Codes: A Sickle Cell Podcast is made possible by Agios Pharmaceuticals Inc. Visit Agios.com to learn more. The following Agios-supported programs are intended for informational and educational purposes only and are not intended as medical advice. Please speak with your healthcare professional before making any treatment decisions. Hosts and guests featured in this episode have been compensated for their time.   Join an inclusive community and build connections with other hemolytic anemia allies by following @AllyVoicesRising on Instagram.  

Dr. Eric Kmiec is Director of the Gene Editing Institute of the Helen F. Graham Cancer and Research Institute at Christiana Care Health System. He also holds faculty appointments at the University of Delaware and the Wistar Institute. Eric and his colleagues are working to develop new ways to treat cancer by destroying the genes that cause cancer cells to be resistant to typical therapies like chemotherapy, radiation, or immunotherapy. Throughout his life, Eric has enjoyed sports. He particularly likes playing baseball and hockey, and he still plays baseball competitively in a league in Philadelphia. Eric also spends much of his time doing landscaping and yard work. He Received his B.A. in Microbiology from Rutgers University, his M.S. in Cell Biology and Biochemistry from Southern Illinois University, and his Ph.D. in Molecular Biology and Biochemistry from the University of Florida School of Medicine. He conducted postdoctoral research at the University of Rochester before joining the faculty at the University of California, Davis in 1987. Since then, he has served on the faculty of Thomas Jefferson University, the University of Delaware, and Delaware State University. In addition, Eric founded, consulted for, and served as Vice President of Kimeragen, Inc., he was Chief Scientific Advisor for the Genomics Division of Tapestry Pharmaceuticals, was an Eminent Scholar and Director of the Marshall University Institute for Interdisciplinary Research, and also served as Co-Founder, Chief Scientific Officer, and a Board Member of OrphageniX. Eric has received numerous awards and honors over the course of his career, including receipt of the 2012 Proudford Foundation Unsung Hero Award in Sickle Cell Disease, designation as an Honorary Commander of the 436th Air Wing at Dover Air Force Base in 2013 and 2014, and also induction into the Southern Illinois University, Edwardsville Alumni Hall of Fame in 2012. Further, Eric and the team at the Gene Editing Institute were recently awarded the inaugural Life Sciences and Bio Innovation Award from the Philadelphia-Israeli Chamber of Commerce. In our interview, Eric shared his experiences in life and science.